Nonprofit group gains right to develop rilpivirine for HIV prevention

09/25/2013 | Genetic Engineering & Biotechnology News

PATH, an international nonprofit organization, has been granted rights through a deal with Janssen R&D of Ireland to develop an injectable form of the HIV-1 drug rilpivirine as a potential preventive treatment for HIV. Backed by the Bill & Melinda Gates Foundation, PATH plans to carry out prophylaxis trials in partnership with the HIV Prevention Trials Network and the NIH's AIDS division. PATH and Janssen could enter a late-stage development deal based on the results of the trial.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX